Regardless of whether or not anti-CD38 IgE becomes a MM therapeutic, the present studies support the use of IgE-based therapy targeting different antigens for the treatment of MM and potentially other hematopoietic malignancies. The gene discussed is IGHE; the disease is Miyoshi myopathy.